Tag: ers

Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders

— Founded on the first and only platform designed to genetically engineer small molecule therapeutics from fungi and plants — — Led by veteran biotech executives Usman Azam, Chief Executive Officer, and Fred Grossman, Chief Medical Officer — NEW YORK & CAMBRIDGE, England, October 18, 2022–(BUSINESS WIRE)–Empyrean Neuroscience, Inc., a…

Continue Reading Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders

Gene Editing Tools Market – New Technological Development Projecting Massive Growth till 2029

According to latest research by FMI, the global gene editing tools market trend is estimated to have accounted for more than US$ 481.3 Mn in terms of value in 2022. The report on the gene editing tools market further projects that the gene editing tools market is likely to grow at a CAGR…

Continue Reading Gene Editing Tools Market – New Technological Development Projecting Massive Growth till 2029

GenScript, Avectas Partner on Cell Therapy Manufacturing

NEW YORK – GenScript and Ireland’s Avectas said on Tuesday that they’re partnering to develop a non-viral cell therapy manufacturing process. Under the terms of the agreement, their research teams will apply Avectas’ Solupore technology to permeabilize target cell membranes to deliver GenScript’s GenCRISPR single guide RNA, CRISPR-Cas9 protein, and GenExact…

Continue Reading GenScript, Avectas Partner on Cell Therapy Manufacturing

ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

Lepton Pharmaceutical LTD is a biotechnology company developing a proprietary, breakthrough technology (Castling Technology) to substantially improve adaptive cell-mediated immune response (T-cells, CAR-T-cells, NK-cells.) Dr. Daniel Zurr, CEO of Lepton said: “We are very pleased to establish this relationship and license agreement with ERS Genomics. It will greatly assist us…

Continue Reading ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

Conducting Respiratory Oscillometry in an Outpatient Setting

Respiratory telemetry is a different modality of the pulmonary function testing that is now increasingly used in the clinical and research setting. Oscillometry is conducted through tighter breathing with three acceptable measurements, and can be performed with minimal contraindications. The main advantage of respiratory oscillometry is that it requires minimal…

Continue Reading Conducting Respiratory Oscillometry in an Outpatient Setting

CVC maintains strong US patent portfolio covering CRISPR/Cas9 despite PTAB ruling, reports ERS Genomics

The PTAB decision makes a clear distinction between the CVC applications involved in the interference and CVC’s large portfolio of issued US patents that were not involved in this interference, stating that; “There is no dispute in this proceeding that the CVC inventors conceived of a generic sgRNA CRISPR-Cas9 system…

Continue Reading CVC maintains strong US patent portfolio covering CRISPR/Cas9 despite PTAB ruling, reports ERS Genomics

Regulating gene-editing technology

A chara, – As CEO of ERS Genomics, founded by Emmanuelle Charpentier, Nobel Prize winner for the discovery of Crispr/Cas9, I’d like to echo the sentiments of Dr Thomas McLoughlin (Letters, December 16th), who writes: “Crispr has the potential to revolutionise agriculture, environment and medicine for the benefit of people…

Continue Reading Regulating gene-editing technology

Potter Clarkson and ERS Genomics to join forces with eureKARE on the eureKAWARDS

Potter Clarkson and ERS Genomics to join forces with eureKARE on the eureKAWARDS Potter Clarkson to offer the winner a Kick-StartiP consultancy ERS Genomics to provide the most promising CRISPR/Cas9 team with a complimentary three-year CRISPR/Cas9 license Luxembourg and Paris, France – 14 September 2021: eureKARE (“the Company”), a pioneering…

Continue Reading Potter Clarkson and ERS Genomics to join forces with eureKARE on the eureKAWARDS

ERS Genomics Licenses CRISPR-Cas9 Patent And Technology To Cellular Engineering Technologies – Food, Drugs, Healthcare, Life Sciences

India: ERS Genomics Licenses CRISPR-Cas9 Patent And Technology To Cellular Engineering Technologies 02 September 2021 Khurana and Khurana To print this article, all you need is to be registered or login on Mondaq.com. Recently, Dublin, Ireland-based biotechnology company, ERS Genomics Limited (“ERS”),…

Continue Reading ERS Genomics Licenses CRISPR-Cas9 Patent And Technology To Cellular Engineering Technologies – Food, Drugs, Healthcare, Life Sciences

Global Roundup: Cellink Transitions into BICO

Sweden’s Cellink AB has rebranded to BICO, the world’s first Bio-Convergence company. BICO is the parent company overseeing the 11 subsidiaries, including Cellink Bioprinting. This transition is expected to enable BICO and its subsidiaries to innovate through the group’s shared bio convergence agenda, which entails investments in bioengineering, technology development,…

Continue Reading Global Roundup: Cellink Transitions into BICO

ERS Genomics and Cellular Engineering Technologies collaborating

ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement. Under the agreement, Cellular Engineering Technologies licences the rights from Dublin-based ERS Genomics Ltd. to develop, manufacture and commercialise next-generation stem cell lines using the CRISPR-Cas9 technology initially patented by Emmanuelle Charpentier. Cell manufacturing specialist Cellular Engineering…

Continue Reading ERS Genomics and Cellular Engineering Technologies collaborating